p19 INK4D/CDKN2D Antibody (0.N.485): sc-71807

p19 INK4D Antibody (0.N.485) is a mouse monoclonal IgG1 antibody that detects p19 INK4D in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). p19 INK4D plays a crucial role in regulating the cell cycle by specifically inhibiting the kinase activities of cyclin-dependent kinases Cdk4 and Cdk6, which are essential for the transition from the G1 phase to the S phase of the cell cycle. This inhibition helps prevent uncontrolled cell proliferation, a hallmark of cancer. p19 INK4D expression reaches maximum levels during the S phase, and overexpression can lead to G1 arrest, acting as a critical checkpoint in cellular growth and division. The gene encoding p19 INK4D is located on chromosome 9p21.3, a region frequently associated with chromosomal abnormalities in various human tumors, highlighting potential significance in cancer research and therapeutic strategies. Through interactions with key regulatory proteins in the cell cycle, p19 INK4D serves as an important target for studies aimed at understanding cell cycle dynamics and mechanisms underlying tumorigenesis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p19 INK4D/CDKN2D Antibody (0.N.485) References:

1. Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme.  |  Lam, PY., et al. 2000. Br J Neurosurg. 14: 28-32. PMID: 10884881
2. p19(Ink4d) and p21(Cip1) collaborate to maintain the postmitotic state of auditory hair cells, their codeletion leading to DNA damage and p53-mediated apoptosis.  |  Laine, H., et al. 2007. J Neurosci. 27: 1434-44. PMID: 17287518
3. CDK2 and PKA mediated-sequential phosphorylation is critical for p19INK4d function in the DNA damage response.  |  Marazita, MC., et al. 2012. PLoS One. 7: e35638. PMID: 22558186
4. p19INK4d is involved in the cellular senescence mechanism contributing to heterochromatin formation.  |  Sonzogni, SV., et al. 2014. Biochim Biophys Acta. 1840: 2171-83. PMID: 24667034
5. CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma.  |  Kannan, K., et al. 2014. PLoS Genet. 10: e1004216. PMID: 24675677
6. p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging.  |  Hilpert, M., et al. 2014. Stem Cell Reports. 3: 1085-102. PMID: 25458892
7. Regulation of proliferation in developing human tooth germs by MSX homeodomain proteins and cyclin-dependent kinase inhibitor p19INK4d.  |  Kero, D., et al. 2017. Organogenesis. 13: 141-155. PMID: 28933666
8. Identification of Cdk8 and Cdkn2d as New Prame-Target Genes in 2C-like Embryonic Stem Cells.  |  Lucci, V., et al. 2022. Genes (Basel). 13: PMID: 36292630
9. LINC01012 upregulation promotes cervical cancer proliferation and migration via downregulation of CDKN2D.  |  Zhang, K., et al. 2023. Oncol Lett. 25: 124. PMID: 36844616
10. Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases.  |  Okuda, T., et al. 1995. Genomics. 29: 623-30. PMID: 8575754

The preferred p19 INK4D/CDKN2D antibody is p19 INK4D/CDKN2D Antibody (DCS-100): sc-56334.